OTC · RDGL
Healthcare · Medical - Devices
$0.05
Down-$0.00 (-1.08%)
Updated Aug 22, 2026, 8:41 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RDGL does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning RDGL.
RDGL research
Company profile and research snapshot.
VIVOS INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Jun 11, 2026
The approval allows Vivos to begin in-house manufacturing of IsoPet and supports broader commercialization of its veterinary cancer treatment platform. Key Investor TakeawaysVivos Inc.
Yahoo · Jun 11, 2026
Vivos Therapeutics (VVOS) said Thursday it plans to file a registration statement with the US Securi
Yahoo · Jun 11, 2026
LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including mild-to-severe obstructive sleep apnea (“OSA”), today announced that it intends to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed rights offering purs
Yahoo · Jun 11, 2026
Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that it has received its State of Washington Radioactive Materials License for the manufacturing of IsoPet®. This approval represents a significant regulatory milestone for the Company’s animal health division. It clears the way for in-house production of IsoPet® at Vivos’ new domestic m
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RDGL.
No results
No recent SID articles mention RDGL.
